What amount sold does Microbion Corp report in Form D filings?

The latest linked filings report $45.7M sold across 6 identified offering(s). 0 unlinked amendment(s) are excluded; 0 offering(s) have no reported amount sold. This is not verified lifetime funding or money raised during a specific period.

When was Microbion Corp's most recent SEC filing?

Microbion Corp's most recent Form D filing was on 2021-07-27.

How many investors does Microbion Corp have?

The most recent Form D filing lists 18 investor(s).

What type of securities does Microbion Corp offer?

Microbion Corp's SEC Form D filings indicate equity offerings.

Microbion Corp

CIK: 0001318639·Pharmaceuticals·BOZEMAN, MT·Corporation

Reported Sold

$45,718,424

Total Filings

Identified Offerings

Last Filed

Jul 27, 2021

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately.

About

Company in Biotechnology industry

SEC EDGAR

Offering filing timeline

Jul 27, 2021Form D/A — Amendment

Reported sold: $11,890,627 · Target: $13,390,627

Rule 506(b)·18 investors

Changed: Reported amount sold, Offering target, Reported investors

Mar 31, 2021Form D/A — Amendment

Reported sold: $4,106,048 · Target: $5,606,048

Rule 506(b)·15 investors

Changed: Reported amount sold, Offering target, Reported investors

Jan 25, 2021Form D — New notice

Reported sold: $1,999,999 · Target: $1,999,999

Rule 506(b)·1 investor

Jan 13, 2017Form D — New notice

Reported sold: $25,373,967 · Target: $51,258,964

Rule 506(b)·11 investors

Jan 22, 2016Form D/A — Amendment

Reported sold: $5,861,141 · Target: $8,500,000

Rule 506(b)·33 investors

Changed: Reported amount sold, Reported investors

Jan 21, 2015Form D/A — Amendment

Reported sold: $3,343,067 · Target: $8,500,000

Rule 506(b)·19 investors

Changed: Reported amount sold, Offering target, Reported investors

Jan 22, 2014Form D — New notice

Reported sold: $100,000 · Target: $3,825,000

Rule 506(b)·1 investor

Apr 3, 2013Form D/A — Amendment

Reported sold: $1,246,025 · Target: $1,499,998

Rule 506·19 investors

Changed: Reported amount sold, Offering target, Reported investors

Oct 26, 2012Form D — New notice

Reported sold: $224,996 · Target: $1,100,000

Rule 506·4 investors

Sep 15, 2011Form D/A — Amendment

Reported sold: $932,664 · Target: $2,074,999

Rule 506·22 investors

Changed: Reported amount sold, Reported investors

Aug 11, 2010Form D — New notice

Reported sold: $199,374 · Target: $2,074,999

Rule 506·4 investors

Nov 9, 2009Form D — New notice

Reported sold: $414,000 · Target: $414,000

Rule 506·12 investors

Fundraising Profile

Exemptions

Rule 506(b)

Investors in latest filing

Revenue Range

Decline to Disclose

Reported commissions across identified offerings

Amendment Rate

50%

Latest reported sold across 6 identified offerings

$45,718,424

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

Key People

Jason Harmon

Related Person

Appears on 9 filings

Karim Lalji

Related Person

Appears on 9 filings

Brett Baker

Related Person

Appears on 9 filings

Rodger May

Related Person

Appears on 5 filings

Frank Kerins

Related Person

Appears on 5 filings

Julia Levy

Related Person

Appears on 5 filings

Steven Schellong

Related Person

Appears on 5 filings

Jarret Sha

Related Person

Appears on 3 filings

Filing History

Date	Type	Offering target	Reported sold	Investors
Jul 27, 2021	Amendment	$13,390,627	$11,890,627	18
Mar 31, 2021	Amendment	$5,606,048	$4,106,048	15
Jan 25, 2021	New	$1,999,999	$1,999,999	1
Jan 13, 2017	New	$51,258,964	$25,373,967	11
Jan 22, 2016	Amendment	$8,500,000	$5,861,141	33
Jan 21, 2015	Amendment	$8,500,000	$3,343,067	19
Jan 22, 2014	New	$3,825,000	$100,000	1
Apr 3, 2013	Amendment	$1,499,998	$1,246,025	19
Oct 26, 2012	New	$1,100,000	$224,996	4
Sep 15, 2011	Amendment	$2,074,999	$932,664	22
Aug 11, 2010	New	$2,074,999	$199,374	4
Nov 9, 2009	New	$414,000	$414,000	12

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

EIKONOKLASTES THERAPEUTICS, INC.

Pharmaceuticals

Offering target: $18,638,880

Filed Oct 5, 2026